Results
Title

Ridaforolimus 体外单独或联合氟康唑抗念珠菌作用的研究.

Authors

谭静文; 宋金凤; 刘小萍; 高志琴; 杨虹; 杨连娟

Abstract

Candida albicans is the leading fungal human pathogen causing life-threatening infection in immunocompromised individuals. Fluconazole is the most prevalent antifungal drug in clinical use, but its therapeutic efficacy is compromised by the emergence of drug resistant strains. Looking for new antifungal targets or chemical compounds capable of enhancing the antifungal abilities so as to replace existing antifungal drugs is urgently needful. We found TOR signal passway inhibitor ridaforolimus had ability to resist common Candida species. In this study, in vitro effect of ridaforolimus alone and in combination with fluconazole against Candida spp. was tested through disk diffusion and standardized broth microdilution methods. The results showed that ridaforolimus alone had great anti-Candida ability. It can also enhance fluconazole and change fluconazole’s function of fungistasis into fungicidal function, thereby reversing resistance of C. albicans to fluconazole. Our data indicate that ridaforolimus has great potential for further use to treat invasive candidiasis

Subjects

CANDIDA albicans; DRUG abuse; FLUCONAZOLE; CANDIDA; INVASIVE candidiasis; CANDIDEMIA; DISC diffusion tests (Microbiology)

Publication

Mycosystema, 2019, Vol 38, Issue 8, p1371

ISSN

1672-6472

Publication type

Academic Journal

DOI

10.13346/j.mycosystema.190095